Smivet BV is proud to announce the recent validation of its IP applications for an in vitro produced Tetanus Antitoxin for human and veterinary use, #onehealth. Patents were granted and

Smivet BV is proud to announce that RL490, an in vitro produced tetanus antitoxin single-domain antibody trimer, proved again its capability to neutralise this for animals and humans deadly toxin.

Smivet BV has recently published a peer-reviewed scientific paper on the development of its single-domain antibody (SDA) platform to extent the serum half life of biologics in multiple animal species.

Smivet BV and SYVA (Leon, Spain) have entered into a partnership and are expanding their collaboration.

Smivet has invested in the use of the Antibody-ExtractorTM software platform of Abnomx to analyse its NGS libraries.

The website has been updated! Smivet has visited the 2022 Festival of Biologics event in Basel, Switserland.

A peer reviewed scientific publication (De Smit et al. 2021) is now available reporting the research performed by Smivet on the development of a life saving new and innovative Tetanus

In a clinical study the proof of concept stage with the lead SDA Tetanus Antitoxin has been fully completed in the target species (Horses). The study confirmed the earlier findings

A Smivet patent application that protects Smivets proprietary SDA libraries has entered the international PCT procedure.